Mary Chapman,  features writer—

For Pat Quinn, co-founder of the ALS Ice Bucket Challenge, everyday communication has become more challenging as his amyotrophic lateral sclerosis (ALS) disease has progressed. But eye-tracking technology has helped him, in a sense, retain his “voice.” In fact, Quinn recounts a time when inadvertently letting his…

Three Canadian provinces — Ontario, New Brunswick, and Alberta — have added Radicava (edaravone), a treatment for with amyotrophic lateral sclerosis (ALS), to their provincial medication plans. These recent but separate actions mean that Mitsubishi Tanabe Pharma’s intravenous infusion therapy is now listed on each province’s individual public…

The National Institutes of Health (NIH) is investing $25 million over five years in a program to encourage innovative research that deepens our understanding of  amyotrophic lateral sclerosis (ALS), with a goal of better treating the disease. Called Accelerating Leading-edge Science in ALS (ALS2), the initiative aims at…

Each June 21 marks Global Day 2020, 24 hours set aside to heighten awareness of amyotrophic lateral sclerosis (ALS) and to raise money to fight it. Ample ways exist to participate in the worldwide event that’s coordinated by the International Alliance of ALS/MND Associations, whose member organizations…

The ALS Association and I AM ALS have awarded BrainStorm Cell Therapeutics $500,000 to support an amyotrophic lateral sclerosis (ALS) biomarker study based on the biotechnology company’s pivotal trial into its NurOwn therapy. Specifically, the combined grant — $400,000 is from the ALS Association —…

Mitsubishi Tanabe Pharma America (MTPA) has set up a support program for adults living with amyotrophic lateral sclerosis (ALS) and wanting to learn more about this disease and Radicava (edaravone), an intravenous ALS treatment the company markets in the U.S. Called JourneyMate, the program connects ALS patients…

The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to healthcare, among other…

A student bioengineering team at Washington State University (WSU) has designed a mattress to help amyotrophic lateral sclerosis (ALS) patients and others with sleep or mobility issues rest better. The students — seniors Katie Lober, Jackson Rieb, and Sarah Schroeder — hope to patent their invention and also…

ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities such as outdoor bake…

Grant awards totaling $5 million will support six academic-industry projects into potential biomarkers and treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD), Target ALS and the Association for Frontotemporal Degeneration (AFTD) announced. The two groups joined to support this collaborative work as ALS and…